http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109745333-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c44d4895aa6201081614e533647ab2dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9078cf4fb5cd6f469d285ea16c47fe8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_547dad6ecce9bb716b512685d77d64c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6573538ed401f757d7e07035703179a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d54b81d181deae341964135a97d59f5 |
| publicationDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109745333-A |
| titleOfInvention | A kind of pharmaceutical composition for bladder cancer treatment and application thereof |
| abstract | The present application discloses a pharmaceutical composition for bladder cancer treatment and its application. The pharmaceutical composition of the present application for bladder cancer treatment is composed of doxorubicin and epigallocatechin gallate as active ingredients. The pharmaceutical composition of the present application utilizes the synergistic anti-bladder cancer effect of EGCG and DOX, which not only reduces the overall cardiotoxicity of the pharmaceutical composition, but also has less toxic and side effects on normal bladder urothelial cells. Compared with the single use of DOX, the pharmaceutical composition of the present application has a better inhibitory effect on the growth of bladder cancer cells, not only can better inhibit the migration and infection of bladder cancer cells, but also has a better ability to induce apoptosis of bladder cancer cells Effect. The pharmaceutical composition of the present application provides a new drug with better anti-cancer effect and less toxicity for the treatment of bladder cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115887443-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114181906-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114164176-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114164176-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114181906-A |
| priorityDate | 2017-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 167.